Bioretec will accelerate product development of the RemeOs Spinal Interbody Cage, based on an evaluation following receipt of Breakthrough Device Designation in March 2024.
The device is engineered from a multifunctional, MRI-compatible, absorbable hybrid composite based on the company’s proprietary magnesium alloy (US Patent No. 11,969,519 B1). It is intended to restore intervertebral height and facilitate intervertebral body fusion in the cervical spine, and aims to address the limitations of traditional non-degradable implants by minimizing complications and enhancing patient quality of life.
The potential of the RemeOs Spinal Interbody Cage has been validated by receipt of a patent (EP 3,782,657 B1) for its hybrid composite technology used in the production of the device.
The RemeOs Spinal Interbody Cage has produced highly promising results in simulations and technological proof of concept of the device, fulfilling a key validation point and prerequisite for progressing into preclinical trials in large animal spine, and thereby creating a strong commercial rationale for Bioretec to accelerate the product development of the device. Interest in the potential of the cage has been broad among medical experts.
The device offers alternatives to existing products on the market due to its ability to enhance bone growth and limit stress shielding causing complications.
Bioretec will accelerate product development of the RemeOs Spinal Interbody Cage, based on an evaluation following receipt of Breakthrough Device Designation in March 2024.
The device is engineered from a multifunctional, MRI-compatible, absorbable hybrid composite based on the company's proprietary magnesium alloy (US Patent No....
Bioretec will accelerate product development of the RemeOs Spinal Interbody Cage, based on an evaluation following receipt of Breakthrough Device Designation in March 2024.
The device is engineered from a multifunctional, MRI-compatible, absorbable hybrid composite based on the company’s proprietary magnesium alloy (US Patent No. 11,969,519 B1). It is intended to restore intervertebral height and facilitate intervertebral body fusion in the cervical spine, and aims to address the limitations of traditional non-degradable implants by minimizing complications and enhancing patient quality of life.
The potential of the RemeOs Spinal Interbody Cage has been validated by receipt of a patent (EP 3,782,657 B1) for its hybrid composite technology used in the production of the device.
The RemeOs Spinal Interbody Cage has produced highly promising results in simulations and technological proof of concept of the device, fulfilling a key validation point and prerequisite for progressing into preclinical trials in large animal spine, and thereby creating a strong commercial rationale for Bioretec to accelerate the product development of the device. Interest in the potential of the cage has been broad among medical experts.
The device offers alternatives to existing products on the market due to its ability to enhance bone growth and limit stress shielding causing complications.
Copy to clipboard 
